Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial
Randomized controlled trial published in Archives of disease in childhood (2006)
Abstract
OBJECTIVES: To determine whether the tissue plasminogen activator, alteplase, is more effective than heparin in preventing blood clots developing in children's haemodialysis central lines between dialysis sessions. DESIGN: A prospective double-blind, within-patient multiperiod cross-over controlled trial of instilling a "lock" of either heparin 5000 U/ml or alteplase 1 mg/ml into the central lines of two children haemodialysed twice weekly, and seven dialysed thrice weekly, over 10 weeks. SETTING: A UK paediatric nephrology unit. MAIN OUTCOME MEASURES: Weight of blood clot aspirated from the line at the start of the next dialysis session. RESULTS: The odds of a clot forming was 2.4 times greater with heparin than alteplase (95% CI 1.4 to 4.0; p = 0.001), and when present they were 1.9 times heavier (31 vs 15 mg; 95% CI 1.5 to 2.4; p<0.0005). There was no effect of inter-dialytic interval. One child required an alteplase infusion to clear a blocked line following a heparin lock. We subsequently changed our routine locks from heparin to alteplase. Comparing the year before and after that change, the incidence of blocked lines requiring an alteplase or urokinase infusion fell from 2.7 to 1.2 per child (p<0.03), and the need for surgical replacements from 0.7 to nil (p<0.02). CONCLUSION: Alteplase is significantly more effective than heparin in preventing clot formation in central haemodialysis lines. This reduces morbidity and improves preservation of central venous access. It is more expensive, though relatively economic if packaged into syringes and stored frozen until needed, but reduces the costs of unblocking or replacing clotted lines.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
In a randomised cross-over trial in children's haemodialysis lines, alteplase locks prevented clots better than heparin (odds of clot 2.4 times greater with heparin) and switching to alteplase reduced blocked lines and surgical replacements.
Context
This prospective double-blind, within-patient multiperiod cross-over controlled trial compared alteplase versus heparin as locking solutions to prevent blood clots in pediatric central venous haemodialysis lines in nine children over 10 weeks. The abstract reports that alteplase was significantly more effective than heparin, with 2.4-fold lower odds of clot formation and lighter clots when present. The study examines pharmaceutical anticoagulation management of dialysis catheters. The abstract contains no mention of leeches, hirudotherapy, or any leech-derived compounds.
Citation
Reference (Vancouver style)
Gittins NS, Hunter-Blair YL, Matthews JN, Coulthard MG. Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial. Arch Dis Child. 2007;92(6):499-501. doi:10.1136/adc.2006.100065. PMID: 17068072
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026